132 related articles for article (PubMed ID: 14508164)
1. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome).
Alberini JL; Belhocine T; Hustinx R; Daenen F; Rigo P
Nucl Med Commun; 2003 Oct; 24(10):1081-6. PubMed ID: 14508164
[TBL] [Abstract][Full Text] [Related]
2. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
3. [18F-FDG whole-body positron-emission tomography (PET) in patients with unknown primary tumors].
Matheja P; Schober O
Strahlenther Onkol; 2000 Mar; 176(3):151-2. PubMed ID: 10742838
[No Abstract] [Full Text] [Related]
4. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
[TBL] [Abstract][Full Text] [Related]
5. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
6. [The role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases].
Fülöp M; Kásler M; Remenár E; Lengyel Z; Borbély K
Magy Onkol; 2012 May; 56(2):84-92. PubMed ID: 22629545
[TBL] [Abstract][Full Text] [Related]
7. [18F]FLT PET for diagnosis and staging of thoracic tumours.
Dittmann H; Dohmen BM; Paulsen F; Eichhorn K; Eschmann SM; Horger M; Wehrmann M; Machulla HJ; Bares R
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1407-12. PubMed ID: 12898201
[TBL] [Abstract][Full Text] [Related]
8. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography.
Stoeckli SJ; Mosna-Firlejczyk K; Goerres GW
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):411-6. PubMed ID: 12634970
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
10. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
12. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).
Lassen U; Daugaard G; Eigtved A; Damgaard K; Friberg L
Eur J Cancer; 1999 Jul; 35(7):1076-82. PubMed ID: 10533451
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
15. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma.
Mijnhout GS; Comans EF; Raijmakers P; Hoekstra OS; Teule GJ; Boers M; De Gast GC; Adèr HJ
Nucl Med Commun; 2002 May; 23(5):475-81. PubMed ID: 11973489
[TBL] [Abstract][Full Text] [Related]
16. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
17. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
18. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
Rinne D; Baum RP; Hör G; Kaufmann R
Cancer; 1998 May; 82(9):1664-71. PubMed ID: 9576286
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors.
Jeong HJ; Chung JK; Kim YK; Kim CY; Kim DG; Jeong JM; Lee DS; Jung HW; Lee MC
J Nucl Med; 2002 Nov; 43(11):1432-7. PubMed ID: 12411544
[TBL] [Abstract][Full Text] [Related]
20. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
